The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

SIERRA trial: Does Iomab-B conditioning spare side effects compared with conventional conditioning?

During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Rajneesh Nath, Banner Gateway Medical Center, Gilbert, US. We asked, Does Iomab-B conditioning spare side effects compared with conventional conditioning?

SIERRA trial: Does Iomab-B conditioning spare side effects compared with conventional conditioning?

Nath outlines results from the phase III SIERRA trial, observing the toxicity of lomab-B conditioning in older patients with relapsed/refractory AML. He highlights an improved toxicity profile with Iomab-B conditioning compared with conventional care, including reduced rates of sepsis, febrile neutropenia, and mucositis.

 

Share:
More about...